Literature DB >> 26123039

Kidney cancer: Single nucleotide polymorphisms in mRCC-is their time up?

Benoit Beuselinck1, Jessica Zucman-Rossi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26123039     DOI： 10.1038/nrurol.2015.149

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib.

Authors:  Astrid A M van der Veldt; Karel Eechoute; Hans Gelderblom; Jourik Gietema; Henk-Jan Guchelaar; Nielka P van Erp; Alfons J M van den Eertwegh; John B Haanen; Ron H J Mathijssen; Judith A M Wessels
Journal:  Clin Cancer Res       Date:  2010-11-19       Impact factor: 12.531

2.  CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Authors:  Meta H M Diekstra; Jesse J Swen; Epie Boven; Daniel Castellano; Hans Gelderblom; Ron H J Mathijssen; Cristina Rodríguez-Antona; Jesus García-Donas; Brian I Rini; Henk-Jan Guchelaar
Journal:  Eur Urol       Date:  2015-04-27       Impact factor: 20.096

3.  Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study.

Authors:  Jesus Garcia-Donas; Emilio Esteban; Luis Javier Leandro-García; Daniel E Castellano; Aranzazu González del Alba; Miguel Angel Climent; José Angel Arranz; Enrique Gallardo; Javier Puente; Joaquim Bellmunt; Begoña Mellado; Esther Martínez; Fernando Moreno; Albert Font; Mercedes Robledo; Cristina Rodríguez-Antona
Journal:  Lancet Oncol       Date:  2011-10-17       Impact factor: 41.316

4.  Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662.

Authors:  M H M Diekstra; H J Klümpen; M P J K Lolkema; H Yu; J S L Kloth; H Gelderblom; R H N van Schaik; H Gurney; J J Swen; A D R Huitema; N Steeghs; R H J Mathijssen
Journal:  Clin Pharmacol Ther       Date:  2014-02-24       Impact factor: 6.875

5.  VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis.

Authors:  Benoit Beuselinck; Alexandra Karadimou; Diether Lambrechts; Bart Claes; Pascal Wolter; Gabrielle Couchy; Joost Berkers; Hendrik van Poppel; Robert Paridaens; Patrick Schöffski; Arnaud Méjean; Virginie Verkarre; Evelyne Lerut; Florence Joly; Thierry Lebret; Gwénaelle Gravis; Gael Deplanque; Aurélien Descazeaud; Nathalie Rioux Leclercq; Vincent Molinié; Jean-Jacques Patard; Corine Teghom; Reza Elaidi; Jessica Zucman-Rossi; Stéphane Oudard
Journal:  Acta Oncol       Date:  2013-02-20       Impact factor: 4.089

6.  Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib.

Authors:  Benoit Beuselinck; Diether Lambrechts; Thomas Van Brussel; Pascal Wolter; Nina Cardinaels; Steven Joniau; Evelyne Lerut; Alexandra Karadimou; Gabrielle Couchy; Philippe Sebe; Alain Ravaud; Marc Zerbib; Armelle Caty; Robert Paridaens; Patrick Schöffski; Virginie Verkarre; Julien Berger; Jean-Jacques Patard; Jessica Zucman-Rossi; Stéphane Oudard
Journal:  Acta Oncol       Date:  2014-05-30       Impact factor: 4.089

7.  The effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal cell carcinoma.

Authors:  Tomoyuki Mizuno; Masahide Fukudo; Tsuyoshi Fukuda; Tomohiro Terada; Min Dong; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Toshiya Katsura; Ken-Ichi Inui; Alexander A Vinks; Kazuo Matsubara
Journal:  Ther Drug Monit       Date:  2014-06       Impact factor: 3.681

8.  IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma.

Authors:  C-F Xu; T Johnson; J Garcia-Donas; T K Choueiri; C N Sternberg; I D Davis; N Bing; K C Deen; Z Xue; L McCann; E Esteban; J C Whittaker; C F Spraggs; C Rodríguez-Antona; L N Pandite; R J Motzer
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

9.  Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib.

Authors:  B Beuselinck; A Karadimou; D Lambrechts; B Claes; P Wolter; G Couchy; J Berkers; R Paridaens; P Schöffski; A Méjean; V Verkarre; E Lerut; A de la Taille; J-M Tourani; P Bigot; C Linassier; S Négrier; J Berger; J-J Patard; J Zucman-Rossi; S Oudard
Journal:  Br J Cancer       Date:  2013-03-05       Impact factor: 7.640

10.  Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; Gary R Hudes; Robert A Figlin; Jean-Francois Martini; Patricia A English; Xin Huang; Olga Valota; J Andrew Williams
Journal:  Cancer Chemother Pharmacol       Date:  2014-08-07       Impact factor: 3.333
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.